Optimising Renal Tumour Management Through Artificial Intelligence Modules

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-01-01

Study Completion Date

2033-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to improve the management of people with renal tumour by multimodal artificial intelligence(AI). It will also measure the accuracy of the predictions from AI models. The main questions it aims to answer are:

1. whether the AI module can accurately provide tumor-related information such as Benign or malignant, subtypes, grading, stage, etc. by learning from preoperative CT images.
2. whether the AI module can help clinicians find out the most suitable surgical programme for people with renal tumor.
3. whether the AI module can integrate CT images and pathology slides, offering supplementary prognostic information to improve postoperative survival.

Participants who complete a CT(usually Contrast-enhanced CT, CECT) examination and undergo radical or partial nephrectomy will carry out active surveillance and record postoperative survival data for 5 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Development of AI Model for Renal Tumor Diagnosis Using CT and Lab Tests

NCT06761742

Renal Tumors

COMPLETED

Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment

NCT07118813

Renal Cell Carcinoma (Kidney Cancer)

RECRUITING

Development and Prospective Validation of a Digital Pathology-based Artificial Intelligence Diagnostic Model for Pan-cancer Lymphatic Metastasis

NCT06517979

Cancer Lymphatic Metastasis

RECRUITING

A Study Based on CT Radiomics for Distinguishing Benign From Malignant Renal Tumors and Assessing Their Aggressiveness.

NCT07060248

Renal Cell Carcinoma (RCC)

ACTIVE_NOT_RECRUITING

Multimodal Large Model-Driven Risk and Prognosis Assessment for Brain Metastases in Lung Cancer

NCT07107035

AI (Artificial Intelligence) NSCLC Brain Metastasis

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study, AI model will explore and clarify features in renal tumor CT images and pathological images that are difficult to detect manually, and then correlate them with clinical outcomes, thereby improving the diagnosis and treatment process for renal tumors. Firstly, the model can accurately distinguish renal tumor subtypes and predict stage, grade, and complexity so as to svoid misdiagnosis and assist clinicians in formulating treatment plans. Secondly, by learning from surgical videos, the model can provide additional information during surgerys, such as important anatomical landmarks, location of tumors. Finally, combining radiomics and pathomics, the model can differentiate between high-risk and low-risk patients after surgery, thus providing personalized prognostic guidance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Neoplasms Pathology Renal Cell Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with renal tumor which can be treated by surgery;
* Complete CECT within 30 days before surgery;
* Patients who fully understand this study and sign the informed consent;

Exclusion Criteria

* Patients with any item missing from the baseline clinical and pathological information;
* Patients who has already metastasized by the time the tumor is discovered;
* Previous treatment in any form, including surgery, targeted therapy and immunotherapy;

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No